KERLONE
LOE ApproachingNDAORALTABLET
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 28m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERLONE is an oral small-molecule tablet approved in 1989 by Sanofi. The generic name and mechanism of action are not publicly specified in available data. This product is a mature, branded pharmaceutical approaching loss of exclusivity.
LOE Approaching
As a mature product approaching LOE with moderate competitive pressure (30%), the brand team is likely focused on lifecycle management and defending market share against generic entry rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, KERLONE offers limited career growth opportunities. Professionals on this brand should plan transitions to growth-stage products or support functions within Sanofi's portfolio.
Brand ManagerField Sales Representative
Worked on KERLONE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.